Talaris Therapeutics, Inc. announced that as of December 31, 2022, the company had cash, cash equivalents, and marketable securities of approximately $181.3 million. The company also announced a restructuring plan that includes reducing its workforce by one-third and discontinuing certain clinical development programs.